ENTA—Mavyret’s US new-patient share=56.6% in the week ending 2/1/18, as reported by IMS. GILD’s US new-patient share was 42.6%, and MRK’s was 0.9%.
In the same week: Mavyret’s US total-script share was 51.3%—despite Mavyret’s having a smaller average number of scripts per patient (i.e. a shorter average duration of treatment) than GILD’s HCV products; GILD’s US total-script share was 47.9%, and MRK’s was 0.8%.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.